Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Saved in:
Bibliographic Details
Published inProtein & cell Vol. 12; no. 7; pp. 586 - 591
Main Authors Fu, Wenyu, Chen, Yujianan, Wang, Kaidi, Hettinghouse, Aubryanna, Hu, Wenhuo, Wang, Jing-Quan, Lei, Zi-Ning, Chen, Zhe-Sheng, Stapleford, Kenneth A., Liu, Chuan-ju
Format Journal Article
LanguageEnglish
Published Beijing Higher Education Press 01.07.2021
Springer Nature B.V
Subjects
ACE2
Angiotensin-Converting Enzyme 2
Biochemistry
Biomedical and Life Sciences
Cell Biology
COVID-19
Developmental Biology
Drug Repositioning
Enzyme-Linked Immunosorbent Assay
Human Genetics
Humans
Letter
Life Sciences
Pharmaceutical Preparations
Protein Science
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Stem Cells
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:1674-800X
1674-8018
DOI:10.1007/s13238-020-00803-w